Better Health · Better You

Translating Our Research Findings in Stem Cells Into Clinical Applications

ImStem was incorporated in 2012.

As an innovative biopharmaceutical company,
we aspire to improve patients' treatment outcomes and quality of life,

targeting areas in autoimmune,
degenerative, and rare diseases.


T-MSC technology is based on ImStem’s patented
differentiation technology, which can differentiate
human embryonic stem cells (hESCs) into
mesenchymal stem cells (MSCs) with high efficiency,
consistency, and quality, through a trophoblast-like
intermediate stage.

The MSC derived with this proprietary technology is
called T-MSC.

Currently the clinical trial to study the proprietary T-MSC (IMS001)cell therapy in patients with multiple sclerosis is under way. IMS001 is a human embryonic cell (hESC) derived mesenchymal stem cell (MSC) investigational drug.

The Phase I study is enrolling patients who meet the following criteria.